Yaygın anksiyete bozukluğu olan bir hastada hayatı tehdit eden sitaloprama bağlı hemolitik anemi: Bir olgu sunumu
Öz
Seçici serotonin geri alım inhibitörlerinin hemoliz yan etkisi potansiyel olarak ölümcüldür, ancak çok fazla bildirilmemiştir. Bu yazıda sitalopram 40 mg/gün kullanımı sonrası hemolitik anemi gelişen ve ilacın kesilmesi ile düzelen 43 yaşında erkek bir olguyu sunuyoruz. Hem prevalansı hem de etiyolojisi hakkında daha iyi bilgi sahibi olabilmek için daha fazla çalışma yapılmalıdır.
Anahtar Kelimeler
Sitalopram hemolitik anemi seçici serotonin geri alım inhibitörü
Kaynakça
- 1. Nemeroff CB. Overview of the safety of citalopram. Psychopharmacol Bull. 2003;37:96-121.
- 2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; Author: Washington, DC, 2013.
- 3. Kose S, Akin E, Cetin M. Adverse drug reactions and causality: The Turkish version of Naranjo Adverse Drug Reactions Probability Scale. Psychiatry Clin Psychopharmacol. 2017;27:205-6.
- 4. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf. 1994;10:93-102.
- 5. Pierce A, Nester T, Education Committee of the Academy of Clinical Laboratory Physicians and Scientists. Am J Clin Pathol. 2011;136:7-12.
- 6. Jilani K, Enkel S, Bissinger R, et al. Fluoxetine induced suicidal erythrocyte death. Toxins (Basel). 2013;5:1230-43.
- 7. Garraty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010;24:143-50.
Life-threatening citalopram induced hemolytic anemia in a patient with generalized anxiety disorder: A case report
Öz
The hemolysis side effect of selective serotonin reuptake inhibitors is potentially lethal, although not much has been reported. We hereby report a 43-year-old male case of hemolytic anemia that developed after use of citalopram 40 mg/day and its improvement with discontinuation. Further studies should be conducted to provide a greater understanding of both its prevalence and etiology.
Anahtar Kelimeler
Citalopram hemolytic anemia selective serotonin reuptake inhibitor
Kaynakça
- 1. Nemeroff CB. Overview of the safety of citalopram. Psychopharmacol Bull. 2003;37:96-121.
- 2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; Author: Washington, DC, 2013.
- 3. Kose S, Akin E, Cetin M. Adverse drug reactions and causality: The Turkish version of Naranjo Adverse Drug Reactions Probability Scale. Psychiatry Clin Psychopharmacol. 2017;27:205-6.
- 4. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf. 1994;10:93-102.
- 5. Pierce A, Nester T, Education Committee of the Academy of Clinical Laboratory Physicians and Scientists. Am J Clin Pathol. 2011;136:7-12.
- 6. Jilani K, Enkel S, Bissinger R, et al. Fluoxetine induced suicidal erythrocyte death. Toxins (Basel). 2013;5:1230-43.
- 7. Garraty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010;24:143-50.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | İç Hastalıkları |
| Bölüm | Olgu Sunumu |
| Yazarlar | |
| Yayımlanma Tarihi | 20 Mart 2020 |
| Yayımlandığı Sayı | Yıl 2020 Cilt: 5 Sayı: 1 |
